Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

VERTEX PHARMACEUTICALS INC / MA

Form 4 April 03, 2012

FORM 4

subject to

Section 16.

Form 4 or

obligations

may continue.

Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Washington, D.C. 20549
Check this box
if no longer

CTLATERATE OF CHANGES IN DENERGIAL ON NEED

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

See Instruction 1(b).

C/O VERTEX

(City)

(Print or Type Responses)

1. Name and Address of Reporting Person *
Sachdev Amit

2. Issuer Name **and** Ticker or Trading

Symbol

VERTEX

5. Relationship of Reporting Person(s) to Issuer

VERTEX PHARMACEUTICALS INC / MA [VRTX]

(Check all applicable)

(Last) (First) (Middle)

(Month/Day/Year)

3. Date of Earliest Transaction

X Officer (give title below)

Director

_____ 10% Owner e _____ Other (specify

OMB APPROVAL

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

Estimated average

burden hours per

03/30/2012

0313

(Zin)

low) below) SVP, Corp Affairs & Pub Policy

PHARMACEUTICALS INCORPORATED, 130 WAVERLY

(State)

ST

(Street) 4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

X Form filed by One Reporting Person ____ Form filed by More than One Reporting

Person

CAMBRIDGE, MA 02139

(City)	(State)	Table	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficial						y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactio Code (Instr. 8)	4. Securitin(A) or Dis (Instr. 3, 4)	sposed	of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/30/2012		M		A	\$ 18.93	60,170	D	
Common Stock	03/30/2012		S <u>(1)</u>	26,562	D	\$ 41.01 (2) (3)	33,608	D	
Common Stock							618	I	401(k)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of or Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	\$ 18.93	03/30/2012		M		19,062	08/15/2008	05/14/2018	Common Stock	19,062

Reporting Owners

Relationships Reporting Owner Name / Address Director 10% Owner Officer Other

Sachdev Amit C/O VERTEX PHARMACEUTICALS **INCORPORATED** 130 WAVERLY ST CAMBRIDGE, MA 02139

SVP, Corp Affairs & Pub

Policy

Signatures

Valerie L. Andrews, 04/03/2012 Attorney-In-Fact

**Signature of Reporting Person Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1.
- (2) Open market sales reported on this line occurred at a weighted average price of \$41.01 (range \$40.59 to \$41.34).
- Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2